Giovanni Loureiro Raspantini

Giovanni Loureiro Raspantini

Auto-generated profile, based on publicly available information

Giovanni Loureiro Raspantini

School of Pharmaceutical Science of Ribeirao Preto, University of Sao Paulo (USP), Ribeirao Preto, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
JAJuliana Palma Abriata
Juliana Palma Abriata
RTRoger Casanova Turatti
Roger Casanova Turatti
MLMarcela Tavares Luiz
Marcela Tavares Luiz
GRGiovanni Loureiro Raspantini
Giovanni Loureiro Raspantini
LTLarissa Bueno Tofani
Larissa Bueno Tofani
JMJuliana Maldonado Marchetti
Juliana Maldonado Marchetti

24 October 2018 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
JEJosimar Eloy
Josimar Eloy
RPRaquel Petrilli
Raquel Petrilli
GRGiovanni Loureiro Raspantini
Giovanni Loureiro Raspantini
RLRobert Lee
Robert Lee
Background: RNA interference is a promising therapeutic tool for the treatment of a variety of diseases, with great potential for cancer therapy. Small interfering RNA (siRNA), however, presents several drawbacks that hamper its therapeutic application. Lipid nanoparticles, including liposomes, are delivery systems with great potential for siRNA delivery, protecting it from degradation, enhancing its cell uptake with the ability of controlled release. However, non-specific delivery and side effects could potentially limit the in vivo application. Therefore, targeting lipid nanoparticles to overexpressed receptors of cancer cells represents a strategy for better therapeutic outcome, with improved efficacy and reduced toxicity. For this purpose, lipid nanoparticles could be functionalized with several moieties that can be recognized by cancer cells more than by normal cells. These ligands include folate, transferrin, peptides, oligosaccharides, monoclonal antibodies and aptamers. Methods: In this paper, we reviewed functionalization strategies and addressed the major in vitro and in vivo findings in the field of cancer treatment with siRNA. Results: Many papers showed enhanced siRNA delivery by targeted liposomes, resulting in enhanced drug uptake and better cytotoxicity, with consequent better tumor growth control in xenograft studies. Conclusion: siRNA delivery mediated by functionalized liposomes is promising, but clinical trials need to be conducted.

1 October 2021 in Colloids and Surfaces A: Physicochemical and Engineering Aspects
Verified
Journal Article
Closed access
GRGiovanni Loureiro Raspantini
Giovanni Loureiro Raspantini
MLMarcela Tavares Luiz
Marcela Tavares Luiz
JAJuliana Palma Abriata
Juliana Palma Abriata
JEJosimar Eloy
Josimar Eloy
MVMiguel Menezes Vaidergorn
Miguel Menezes Vaidergorn
JMJuliana Maldonado Marchetti
Juliana Maldonado Marchetti